Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;15(3):e35638.
doi: 10.7759/cureus.35638. eCollection 2023 Mar.

Continuous Ketamine Infusion as a Treatment for Refractory Facial Pain

Roxana Garcia  1 , QiLiang Chen  2 , Edmund Posadas  3 , Johnathan Tran  4 , Albert Kwon  2 , Xiang Qian  2
Affiliations

Continuous Ketamine Infusion as a Treatment for Refractory Facial Pain

Roxana Garcia et al. Cureus. .

Abstract

Complex orofacial pain disorders, such as trigeminal neuralgia (TN) and atypical facial pain (AFP), can be excruciating and debilitating during attacks. Ketamine, an N-methyl-D-aspartate (NMDA) antagonist, is a powerful analgesic that has been used to treat various chronic pain conditions, but its role in treating complex facial pain has only been recently explored. In this retrospective case series, we reviewed the efficacy of continuous ketamine infusion for 12 patients with facial pain refractory to medical treatment. Patients who presented with a diagnosis of TN were more likely to have significant and sustained pain relief after receiving ketamine infusion. By contrast, those who did not respond to the treatment were more likely to have a diagnosis of AFP. The current report suggests a fundamental difference between these two facial pain disorders in their respective underlying pathophysiology and supports the use of continuous ketamine infusion for refractory TN, but not AFP.

Keywords: atypical facial; chronic pain management; ketamine infusion; safety and efficacy; trigeminal neuralgia.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Facial pain beyond trigeminal neuralgia. May A, Hoffmann J. Curr Opin Neurol. 2021;34:373–377. - PubMed
    1. New International Classification of orofacial pain: what is in it for endodontists? Pigg M, Nixdorf DR, Law AS, Renton T, Sharav Y, Baad-Hansen L, List T. J Endod. 2021;47:345–357. - PubMed
    1. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Bendtsen L, Zakrzewska JM, Heinskou TB, et al. Lancet Neurol. 2020;19:784–796. - PubMed
    1. Chronic facial pain: trigeminal neuralgia, persistent idiopathic facial pain, and myofascial pain syndrome-an evidence-based narrative review and etiological hypothesis. Gerwin R. Int J Environ Res Public Health. 2020;17:7012. - PMC - PubMed
    1. Characteristics and natural disease history of persistent idiopathic facial pain, trigeminal neuralgia, and neuropathic facial pain. Ziegeler C, Brauns G, May A. Headache. 2021;61:1441–1451. - PubMed